title: Antithrombotic Selection in ST-Segment Elevation Myocardial Infarction: a Year in Review.
abstract: In ST-segment elevation myocardial infarction (STEMI), interventional cardiologists must move quickly to safely re-establish blood flow while choosing an antithrombotic to preclude wire thrombosis, aid in the restoration of flow, minimize thrombus propagation, and reduce the risk of stent thrombosis. Currently, operators have a choice between heparin and bivalirudin with the possible addition of glycoprotein IIb/IIIa inhibitors (GPIs). Prior studies have shown that bivalirudin use lowers rates of bleeding, but with a clear risk of acute stent thrombosis. Recent studies have examined this question in the modern era of radial access and newer antiplatelet agents. Despite these studies, there remains a question regarding which antithrombotic agent is to be selected in STEMI.
authors.affiliation: St. Louis University School of Medicine, Saint Louis, MO, USA.
authors.forename: Jad
authors.initials: J
authors.lastname: Raffoul
authors.affiliation: St. Louis University School of Medicine, Saint Louis, MO, USA.
authors.forename: Ammar
authors.initials: A
authors.lastname: Nasir
authors.affiliation: St. Louis University School of Medicine, Saint Louis, MO, USA. Andrew.Klein@piedmont.org.|Interventional Cardiology, Vascular and Endovascular Medicine, Piedmont Heart Institute, 275 Collier Road Suite 500, Atlanta, GA, 30309, USA. Andrew.Klein@piedmont.org.
authors.forename: Andrew J P
authors.initials: AJ
authors.lastname: Klein
keywords: Acute stent thrombosis; Coronary artery disease; STEMI; Treatment